iShares Neuroscience and Healthcare ETF
IBRN
2 hedge funds and large institutions have $4.79M invested in iShares Neuroscience and Healthcare ETF in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $4.89M → $4.79M (-$99.3K)
6.45% less ownership
Funds ownership: 98.49% → 92.03% (-6.5%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
-$328K |
IBRN Hedge Fund Activity: Q4 2022 in Review
2 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in iShares Neuroscience and Healthcare ETF (IBRN) for Q4 2022, worth a combined $4.79M — down 2% from $4.89M a quarter earlier.
Fund positioning in IBRN was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Flow Traders U.S., cutting an estimated $328K.
- 2 institutional investors held iShares Neuroscience and Healthcare ETF (IBRN) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $4.79M of iShares Neuroscience and Healthcare ETF stock for Q4 2022, down 2% quarter-over-quarter.
- 0 funds opened new iShares Neuroscience and Healthcare ETF positions in Q4 2022 and 0 closed out.
- The largest iShares Neuroscience and Healthcare ETF seller in Q4 2022 was Flow Traders U.S., an estimated $328K sold.
Based on aggregated 13F filings for Q4 2022.